CLGN (CollPlant Biotechnologies) 3-Year Book Growth Rate : 56.70% (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is CollPlant Biotechnologies 3-Year Book Growth Rate?

CollPlant Biotechnologies's Book Value per Share for the quarter that ended in Sep. 2024 was $1.48.

During the past 12 months, CollPlant Biotechnologies's average Book Value per Share Growth Rate was -47.80% per year. During the past 3 years, the average Book Value per Share Growth Rate was 56.70% per year. During the past 5 years, the average Book Value per Share Growth Rate was 28.60% per year. During the past 10 years, the average Book Value per Share Growth Rate was 24.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

During the past 12 years, the highest 3-Year average Book Value per Share Growth Rate of CollPlant Biotechnologies was 131.60% per year. The lowest was -30.00% per year. And the median was 24.25% per year.

Competitive Comparison of CollPlant Biotechnologies's 3-Year Book Growth Rate

For the Biotechnology subindustry, CollPlant Biotechnologies's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CollPlant Biotechnologies's 3-Year Book Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's 3-Year Book Growth Rate distribution charts can be found below:

* The bar in red indicates where CollPlant Biotechnologies's 3-Year Book Growth Rate falls into.

CollPlant Biotechnologies 3-Year Book Growth Rate Calculation

This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.

CollPlant Biotechnologies (NAS:CLGN) 3-Year Book Growth Rate Explanation

Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.

CollPlant Biotechnologies 3-Year Book Growth Rate Related Terms

Thank you for viewing the detailed overview of CollPlant Biotechnologies's 3-Year Book Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

CollPlant Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CollPlant Biotechnologies Ltd (NAS:CLGN) » Definitions » 3-Year Book Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Oppenheimer Street, P.O. Box 4132, Weizmann Science Park, Rehovot, ISR, 7670104

Website

https://www.collplant.com

CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.